Physician profile
Dan C Phan
NPI 1689899601
$864.15
in general payments reported to CMS, 2019-2025
18 companies · $37.40 in 2025
The $37.40 reported for 2025 was less than what a typical Anatomic Pathology & Clinical Pathology provider received nationally (typical 2025 total: $50.59).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $243 · 2023: $433 · 2024: $151 · 2025: $37.40.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $621.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $621.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $156.35 | 2022-2024 | Dupixent |
| Janssen Biotech, INC. | $147.43 | 2022-2024 | Stelara, Remicade, Simponi Aria |
| Acera Surgical, INC. | $116.66 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $94.27 | 2022-2023 | Entyvio |
| Ardelyx, INC. | $70.27 | 2023 | Ibsrela |
| Alnylam Pharmaceuticals INC. | $46.52 | 2023 | Givlaari |
| Pharmacosmos Therapeutics INC. | $24.93 | 2024 | Monoferric |
| Genzyme Corporation | $24.57 | 2023 | |
| Boston Scientific Corporation | $24.02 | 2025 | General - Pain Management |
| Merck Sharp & Dohme LLC | $22.00 | 2023 | Dificid |
| Roche Diagnostics Corporation | $19.32 | 2022 | |
| Blueprint Medicines Corporation | $18.66 | 2023 | |
| Intercept Pharmaceuticals, INC. | $18.55 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.77 | 2023 | |
| Oxford Immunotec USA INC | $17.66 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Redhill Biopharma INC. | $15.94 | 2023 | |
| Phathom Pharmaceuticals, INC. | $15.85 | 2024 | Voquezna |
| Cequr Corporation | $13.38 | 2025 | Cequr Simplicity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dan Phan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.